47 related articles for article (PubMed ID: 38330918)
1. Nonalcoholic Fatty Liver Disease and Continuous Metabolic Syndrome in Adolescents with Overweight/Obesity.
Ferreira S; Mendes J; Couto D; Ferreira D; Rêgo C
Acta Med Port; 2024 Mar; 37(3):177-186. PubMed ID: 38330918
[TBL] [Abstract][Full Text] [Related]
2. HIF1α Elevations at Tissue and Serum Levels and Their Association With Metabolic Disorders in Children With Obesity.
Zhou N; Zheng W; Peng L; Gao S; Shi Y; Cao M; Xu Y; Sun B; Li X
J Clin Endocrinol Metab; 2024 Apr; 109(5):1241-1249. PubMed ID: 38051959
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a novel non-invasive test for diagnosing nonalcoholic fatty liver disease in Chinese children.
Qin ZW; Ren QN; Zhang HX; Liu YR; Huang K; Wu W; Dong GP; Ni Y; Fu JF
World J Pediatr; 2024 Apr; 20(4):413-421. PubMed ID: 37004681
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation.
Balato N; Napolitano M; Ayala F; Patruno C; Megna M; Tarantino G
World J Gastroenterol; 2015 Jun; 21(22):6892-7. PubMed ID: 26078565
[TBL] [Abstract][Full Text] [Related]
5. Presence of metabolic syndrome markers in very low birth weight ex-premature infants during early adolescence.
Dinerstein A; Aspres N; Nieto R; Saure C; Cimbaro Canella R; Casale MR; Moiron MDC; Kasten L; Benitez A; Galindo A; Conti R
J Pediatr Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38912751
[TBL] [Abstract][Full Text] [Related]
6. A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose.
Jiang W; Jin Q; Li C; Xun Y
Turk J Gastroenterol; 2024 Feb; 35(2):125-135. PubMed ID: 38454244
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of neurology-related proteins are associated with cognitive performance in an older population with overweight/obesity and metabolic syndrome.
Llaurador-Coll M; Rios S; García-Gavilán JF; Babio N; Vilella E; Salas-Salvadó J
Geroscience; 2023 Aug; 45(4):2457-2470. PubMed ID: 36964401
[TBL] [Abstract][Full Text] [Related]
8. What is the disease burden from childhood and adolescent obesity?: a narrative review.
Lee EB
J Yeungnam Med Sci; 2024 Jun; ():. PubMed ID: 38932702
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.
Alkhouri N; Carter-Kent C; Elias M; Feldstein AE
Clin Lipidol; 2011 Jun; 6(3):305-314. PubMed ID: 22162978
[TBL] [Abstract][Full Text] [Related]
10. Reply to the Letter to the Editor on "Prolactin is a Key Factor for Nonalcoholic Fatty Liver Disease in Obese Children".
Zhang J
Horm Metab Res; 2024 Jun; 56(6):472. PubMed ID: 38698580
[TBL] [Abstract][Full Text] [Related]
11. Re: Prolactin is a Key Factor for Nonalcoholic Fatty Liver Disease in Obese Children.
Triebel J; Bertsch T
Horm Metab Res; 2024 Jun; 56(6):471. PubMed ID: 38698579
[No Abstract] [Full Text] [Related]
12. Pediatric Metabolic Syndrome: Pathophysiology and Laboratory Assessment.
Higgins V; Adeli K
EJIFCC; 2017 Mar; 28(1):25-42. PubMed ID: 28439217
[TBL] [Abstract][Full Text] [Related]
13. How and when can we predict the risk of future metabolic disease in children with obesity?
Janson A
Acta Paediatr; 2024 May; 113(5):850-851. PubMed ID: 38411354
[No Abstract] [Full Text] [Related]
14. Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum.
Hepatol Commun; 2023 Feb; 7(2):e0077. PubMed ID: 38345897
[No Abstract] [Full Text] [Related]
15. Perinatal programming of adolescent nonalcoholic fatty liver disease: A case for gender inequality?
Sarkar M; Baffy G
Hepatology; 2018 Jan; 67(1):7-9. PubMed ID: 28771759
[No Abstract] [Full Text] [Related]
16. Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders : A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition.
Lonardo A; Baldelli E
Diabetes Ther; 2020 Apr; 11(4):773-777. PubMed ID: 32146692
[No Abstract] [Full Text] [Related]
17. Clinical evaluation of Lekhaniya Kashaya Vasti in the management of Sthaulya (obesity).
Antiwal M; Singh JP; Tiwari SK
Ayu; 2014 Jan; 35(1):28-34. PubMed ID: 25364196
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic fatty liver disease pathophysiology.
Kountouras J; Zavos C; Vardaka E; Kyrailidi F; Mouratidou MC; Tzitiridou-Chatzopoulou M; Orovou E; Touloumtzi M; Papanikolaou IS; Kazakos E
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38725326
[No Abstract] [Full Text] [Related]
19. Diabetes, nonalcoholic fatty liver disease and obesity: What is the link?
Pustake MV; Giri P; Ganiyani MAMT; Jain S
J Family Med Prim Care; 2024 Mar; 13(3):1119-1120. PubMed ID: 38736789
[No Abstract] [Full Text] [Related]
20. Pharmacological, Endoscopic, Metabolic, and Surgical Procedures for Nonalcoholic Fatty Liver Disease.
Xanthakos SA
Clin Liver Dis (Hoboken); 2021 Mar; 17(3):209-214. PubMed ID: 33868667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
